2.56
price up icon1.99%   0.05
after-market アフターアワーズ: 2.56
loading

Veru Inc (VERU) 最新ニュース

pulisher
Mar 03, 2026

Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha

Mar 03, 2026
pulisher
Mar 02, 2026

Veru : Corporate Presentation, February 2026 - marketscreener.com

Mar 02, 2026
pulisher
Feb 28, 2026

VERU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

VERU Should I Buy - Intellectia AI

Feb 27, 2026
pulisher
Feb 26, 2026

Veru at Oppenheimer Conference: Strategic Insights into Obesity Drug Development - Investing.com

Feb 26, 2026
pulisher
Feb 26, 2026

VERU PE Ratio & Valuation, Is VERU Overvalued - Intellectia AI

Feb 26, 2026
pulisher
Feb 19, 2026

Aug Volume: Is CHGG vulnerable to short sellersJuly 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Feb 19, 2026
pulisher
Feb 19, 2026

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget

Feb 19, 2026
pulisher
Feb 16, 2026

Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - Intellectia AI

Feb 16, 2026
pulisher
Feb 15, 2026

Will Veru Inc. benefit from sector rotationWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

Aug Closing: Can PIII outperform under higher oil pricesAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Feb 14, 2026
pulisher
Feb 13, 2026

Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Nigeria

Feb 13, 2026
pulisher
Feb 12, 2026

Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN

Feb 12, 2026
pulisher
Feb 12, 2026

Veru Q1 2026 earnings preview - MSN

Feb 12, 2026
pulisher
Feb 12, 2026

Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN

Feb 12, 2026
pulisher
Feb 12, 2026

Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey

Feb 12, 2026
pulisher
Feb 11, 2026

Veru Q1 2026 Earnings Call Transcript - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks

Feb 11, 2026
pulisher
Feb 11, 2026

Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada

Feb 11, 2026
pulisher
Feb 11, 2026

Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus

Feb 11, 2026
pulisher
Feb 11, 2026

Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus

Feb 11, 2026
pulisher
Feb 11, 2026

VERU INC. SEC 10-Q Report - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com South Africa

Feb 11, 2026
pulisher
Feb 11, 2026

Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail

Feb 11, 2026
pulisher
Feb 11, 2026

VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks

Feb 11, 2026
pulisher
Feb 11, 2026

VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill

Feb 11, 2026
pulisher
Feb 11, 2026

Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

VERU: Q1 net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch soon - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan

Feb 11, 2026
pulisher
Feb 11, 2026

Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative

Feb 11, 2026
pulisher
Feb 11, 2026

Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan

Feb 11, 2026
pulisher
Feb 11, 2026

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - The Manila Times

Feb 11, 2026
pulisher
Feb 10, 2026

A Look at Veru's Upcoming Earnings Report - Benzinga

Feb 10, 2026
pulisher
Feb 07, 2026

Veru (VERU) price target increased by 11.11% to 25.50 - MSN

Feb 07, 2026
pulisher
Feb 06, 2026

Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on February 11. - 富途牛牛

Feb 06, 2026
pulisher
Feb 04, 2026

Veru (VERU) Price Target Increased by 11.11% to 25.50 - Nasdaq

Feb 04, 2026
pulisher
Feb 04, 2026

Veru Inc. to Host Conference Call for Fiscal 2026 First Quarter Financial Results and Business Update - Quiver Quantitative

Feb 04, 2026
pulisher
Feb 04, 2026

Biopharma Veru sets Feb. 11 webcast on Q1 2026 results - Stock Titan

Feb 04, 2026
pulisher
Feb 04, 2026

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - Yahoo Finance

Feb 04, 2026
pulisher
Jan 30, 2026

Published on: 2026-02-01 18:16:35 - baoquankhu1.vn

Jan 30, 2026
pulisher
Jan 27, 2026

Wall Street Recap: Is Veru Inc a defensive stockJuly 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 27, 2026
pulisher
Jan 23, 2026

Block Trades: Will Veru Inc benefit from AI trends2025 Major Catalysts & Intraday High Probability Setup Alerts - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 21, 2026

Analyzing Verano (OTCMKTS:VRNOF) & Veru (NASDAQ:VERU) - Defense World

Jan 21, 2026
pulisher
Jan 19, 2026

Growth Report: Will Veru Inc benefit from AI trends2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 14, 2026

Veru prices 1.4M shares at $3.00 in underwritten public offering - MSN

Jan 14, 2026
pulisher
Jan 13, 2026

Targets Report: Will Veru Inc stock attract ESG investors2025 Market Sentiment & Real-Time Volume Analysis - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 11, 2026

What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com

Jan 11, 2026
pulisher
Jan 10, 2026

Is Veru Inc. stock a buy in volatile marketsJuly 2025 Final Week & Trade Opportunity Analysis - Улправда

Jan 10, 2026
pulisher
Jan 09, 2026

Why Veru Inc. (FMW) stock trades below fair valueTrade Entry Report & Fast Entry High Yield Tips - ulpravda.ru

Jan 09, 2026
pulisher
Jan 08, 2026

Is Veru Inc. stock attractive after correction2025 Macro Impact & Entry Point Confirmation Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

ulpravda> 2026> How dovish Fed policy supports Veru Inc. (FMW) stockTake Profit & High Conviction Buy Zone Picks - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Why Veru Inc. (FMW) stock remains stableProfit Target & Low Risk High Reward Ideas - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Aug Drivers: Why Veru Inc. (FMW) stock remains stable2025 Stock Rankings & Risk Controlled Stock Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

About UsGreat American Insurance GroupSpecialty Property & Casualty Insurance - FinancialContent

Jan 08, 2026
pulisher
Jan 07, 2026

Veru Inc.Common Stock (NQ: VERU - FinancialContent

Jan 07, 2026
pulisher
Jan 07, 2026

Why Vera Therapeutics Stock Zoomed Higher Today - AOL.com

Jan 07, 2026
pulisher
Jan 06, 2026

Is Veru Inc. (FMW) stock prepared for digital transitionWeekly Market Report & Daily Entry Point Trade Alerts - ulpravda.ru

Jan 06, 2026
pulisher
Jan 05, 2026

User | poteaudailynews.comVeru Inc.Common Stock (Nasdaq:VERU) Stock Quote - FinancialContent

Jan 05, 2026
pulisher
Jan 02, 2026

What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now? - MSN

Jan 02, 2026
pulisher
Dec 30, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Dec 30, 2025
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.57
price down icon 4.21%
biotechnology ONC
$292.94
price down icon 2.03%
大文字化:     |  ボリューム (24 時間):